Skip to main content

NASDAQ:ENDP - Endo International Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $7.67
  • Forecasted Upside: 36.66 %
  • Number of Analysts: 7
  • Breakdown:
  • 2 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$5.61
▲ +0.08 (1.45%)
1 month | 3 months | 12 months
Get New Endo International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ENDP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENDP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$7.67
▲ +36.66% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Endo International in the last 3 months. The average price target is $7.67, with a high forecast of $12.00 and a low forecast of $3.00. The average price target represents a 36.66% upside from the last price of $5.61.

Hold

The current consensus among 7 contributing investment analysts is to hold stock in Endo International. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 2 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 2 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 2 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 2 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 2 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/7/2021Royal Bank of CanadaInitiated CoverageSector Perform$7.00High
i
3/9/2021Morgan StanleyBoost Price TargetUnderweight$5.00 ➝ $7.00High
i
3/8/2021BarclaysBoost Price TargetPositive ➝ Equal Weight$6.00 ➝ $7.00High
i
3/4/2021CitigroupLower Price Target$11.00 ➝ $10.00High
i
3/3/2021Morgan StanleyBoost Price TargetUnderweight$5.00 ➝ $7.00High
i
2/8/2021SVB LeerinkReiterated RatingMarket PerformLow
i
Rating by A. Fadia at SVB Leerink LLC
1/19/2021CitigroupBoost Price Target$7.00 ➝ $9.00High
i
1/4/2021Piper SandlerBoost Price TargetOverweight$6.00 ➝ $12.00N/A
i
11/12/2020Morgan StanleyBoost Price TargetUnderweight$3.00 ➝ $4.00Medium
i
10/9/2020Piper SandlerBoost Price TargetOverweight$5.00 ➝ $6.00High
i
7/27/2020The Goldman Sachs GroupInitiated CoverageSell$3.00High
i
7/8/2020SunTrust BanksReiterated RatingBuyHigh
i
6/11/2020Royal Bank of CanadaReiterated RatingHold$6.00Medium
i
5/10/2020Royal Bank of CanadaReiterated RatingHold$6.00Low
i
4/24/2020CitigroupInitiated CoverageBuy$7.00High
i
4/15/2020Piper SandlerLower Price TargetOverweight$7.00 ➝ $6.00Medium
i
4/2/2020Royal Bank of CanadaReiterated RatingHold$6.00Low
i
4/2/2020Morgan StanleyLower Price TargetUnderweight$4.00 ➝ $3.00Low
i
1/3/2020Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$5.00 ➝ $7.00Low
i
8/9/2019Morgan StanleySet Price TargetSell$2.00N/A
i
Rating by David Risinger at Morgan Stanley
8/8/2019Royal Bank of CanadaReiterated RatingHold$6.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
8/7/2019MizuhoReiterated RatingHold$6.00High
i
Rating by Irina Rivkind Koffler at Mizuho
7/31/2019MizuhoReiterated RatingHold$6.00High
i
Rating by Irina Rivkind Koffler at Mizuho
7/15/2019Morgan StanleyDowngradeEqual Weight ➝ Underweight$8.00 ➝ $3.00Medium
i
7/11/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$11.00 ➝ $6.00High
i
6/17/2019CitigroupDowngradeBuy ➝ Neutral$19.00 ➝ $5.00Medium
i
6/12/2019Cantor FitzgeraldLower Price TargetNeutral$18.00 ➝ $4.75High
i
6/11/2019BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$6.00High
i
5/15/2019Canaccord GenuityLower Price TargetBuy$17.00 ➝ $15.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
5/14/2019MizuhoSet Price TargetHold$9.00Low
i
Rating by Irina Rivkind Koffler at Mizuho
5/13/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$9.00High
i
3/27/2019GabelliReiterated RatingHoldMedium
i
Rating by K. Kedra at Gabelli
3/19/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$13.00Medium
i
3/18/2019JPMorgan Chase & Co.Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $10.00Low
i
3/8/2019Canaccord GenuitySet Price TargetBuy$17.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
3/5/2019SVB LeerinkDowngradeOutperform ➝ Market PerformLow
i
Rating by A. Fadia at SVB Leerink LLC
3/1/2019Piper Jaffray CompaniesReiterated RatingHoldHigh
i
Rating by David Amsellem at Piper Jaffray Companies
11/26/2018MizuhoLower Price TargetNeutral$15.00High
i
11/9/2018Canaccord GenuityUpgradeHold ➝ Buy$16.00 ➝ $20.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
11/9/2018CowenReiterated RatingHold$9.00Low
i
10/19/2018Cantor FitzgeraldBoost Price TargetNeutral ➝ Neutral$12.00 ➝ $18.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
9/11/2018The Goldman Sachs GroupUpgradeSell ➝ Neutral$14.00 ➝ $15.00Low
i
Rating by Dana Flanders at The Goldman Sachs Group, Inc.
8/17/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $17.00Low
i
8/14/2018MizuhoBoost Price TargetNeutral$17.00Low
i
8/13/2018Canaccord GenuityReiterated RatingHold ➝ Hold$13.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
8/13/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$26.00High
i
8/10/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$9.00 ➝ $16.00Low
i
8/9/2018SVB LeerinkBoost Price TargetOutperform ➝ Market Perform$12.00 ➝ $18.00High
i
8/9/2018Stifel NicolausBoost Price TargetHold ➝ Hold$10.00 ➝ $17.00Low
i
8/9/2018CitigroupBoost Price TargetBuy ➝ Buy$11.00 ➝ $19.00Low
i
Rating by Liav Abraham at Citigroup Inc.
8/8/2018Cantor FitzgeraldSet Price TargetHold$12.00High
i
Rating by Louise Chen at Cantor Fitzgerald
8/7/2018B. RileyBoost Price TargetBuy ➝ Buy$13.00 ➝ $15.00Low
i
Rating by D. Buck at B. Riley
8/1/2018Canaccord GenuitySet Price TargetHold$13.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
7/23/2018Cantor FitzgeraldSet Price TargetHold$12.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
7/18/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy$11.00Low
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
7/11/2018CitigroupReiterated RatingBuyLow
i
Rating by Liav Abraham at Citigroup Inc.
6/28/2018B. RileyBoost Price TargetBuy ➝ Buy$10.00 ➝ $13.00High
i
Rating by D. Buck at B. Riley
6/27/2018CitigroupUpgradeNeutral ➝ Buy$11.00High
i
6/1/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy$10.00Medium
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
5/13/2018OppenheimerReiterated RatingHoldLow
i
Rating by Christopher Liu at Oppenheimer Holdings Inc.
5/8/2018Canaccord GenuitySet Price TargetHold$7.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
5/8/2018Cantor FitzgeraldSet Price TargetHold$7.00High
i
Rating by Louise Chen at Cantor Fitzgerald
4/4/2018MizuhoDowngradeBuy ➝ Neutral$12.00 ➝ $7.00High
i
3/10/2018BarclaysSet Price TargetHold$9.00Low
i
Rating by Douglas Tsao at Barclays PLC
3/5/2018BMO Capital MarketsLower Price TargetMarket Perform ➝ Market Perform$10.00 ➝ $9.00High
i
2/28/2018GabelliDowngradeBuy ➝ HoldHigh
i
Rating by K. Kedra at Gabelli
2/27/2018OppenheimerReiterated RatingHoldHigh
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
2/27/2018Canaccord GenuitySet Price TargetHold$7.00High
i
Rating by Dewey Steadman at Canaccord Genuity
2/27/2018Cantor FitzgeraldSet Price TargetHold$7.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
2/26/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
i
2/23/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $10.00High
i
2/21/2018Canaccord GenuitySet Price TargetHold ➝ Hold$8.00 ➝ $7.00Medium
i
Rating by Dewey Steadman at Canaccord Genuity
2/14/2018B. RileyInitiated CoverageBuy ➝ Buy$10.00High
i
Rating by D. Buck at B. Riley
1/11/2018Cantor FitzgeraldSet Price TargetHold$7.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
1/3/2018MizuhoReiterated RatingBuy ➝ Buy$14.00 ➝ $12.00High
i
1/2/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$12.00High
i
Rating by A. Fadia at SVB Leerink LLC
12/12/2017GuggenheimInitiated CoverageNeutral ➝ Neutral$8.50Low
i
Rating by Louise Chen at Guggenheim
11/10/2017Piper Jaffray CompaniesReiterated RatingHold$7.00N/A
i
11/10/2017MizuhoReiterated RatingBuyN/A
i
11/10/2017BMO Capital MarketsLower Price TargetMarket Perform$11.00 ➝ $10.00N/A
i
11/10/2017Cantor FitzgeraldLower Price TargetNeutral$9.00 ➝ $7.00N/A
i
Rating by Louise Chen at Cantor Fitzgerald
11/10/2017CitigroupLower Price TargetNeutral$9.00 ➝ $7.00N/A
i
11/10/2017Royal Bank of CanadaLower Price TargetSector Perform ➝ Sector Perform$9.00 ➝ $8.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
10/30/2017Cantor FitzgeraldSet Price TargetHold$9.00N/A
i
Rating by Louise Chen at Cantor Fitzgerald
10/17/2017Royal Bank of CanadaSet Price TargetHold$9.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
9/28/2017The Goldman Sachs GroupInitiated CoverageSell ➝ Sell$7.00High
i
9/17/2017Piper Jaffray CompaniesReiterated RatingHold$9.00Medium
i
9/12/2017MizuhoReiterated RatingBuy$19.00 ➝ $14.00Low
i
8/14/2017Canaccord GenuitySet Price TargetHold$10.00High
i
Rating by Dewey Steadman at Canaccord Genuity
8/11/2017BMO Capital MarketsReiterated RatingMarket Perform$15.00 ➝ $11.00Low
i
8/10/2017Morgan StanleyLower Price TargetEqual Weight$12.00 ➝ $8.00Low
i
8/10/2017CowenReiterated RatingHold$16.00High
i
8/10/2017CitigroupReiterated RatingNeutral$14.00 ➝ $11.00High
i
8/10/2017MizuhoReiterated RatingBuy$19.00High
i
8/10/2017Royal Bank of CanadaSet Price TargetHold$15.00 ➝ $9.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
8/9/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$15.00 ➝ $13.00Low
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
8/9/2017Royal Bank of CanadaReiterated RatingSector Perform$15.00 ➝ $9.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
8/8/2017OppenheimerReiterated RatingHoldHigh
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
8/8/2017Cantor FitzgeraldSet Price TargetHold$12.00 ➝ $9.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
7/23/2017OppenheimerReiterated RatingHoldHigh
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
7/16/2017Royal Bank of CanadaSet Price TargetHold$15.00Medium
i
Rating by Randall Stanicky at Royal Bank of Canada
7/7/2017Deutsche Bank AktiengesellschaftLower Price TargetBuy$18.00 ➝ $15.00Medium
i
6/17/2017GuggenheimInitiated CoverageHold$12.00Medium
i
Rating by Louise Chen at Guggenheim
6/16/2017Cantor FitzgeraldInitiated CoverageNeutral ➝ Neutral$12.00Low
i
6/14/2017William BlairReiterated RatingMarket PerformLow
i
6/12/2017Royal Bank of CanadaSet Price TargetHold$15.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
6/9/2017Stifel NicolausDowngradeBuy ➝ Hold$22.00 ➝ $15.00High
i
6/8/2017OppenheimerReiterated RatingHoldHigh
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
6/8/2017Canaccord GenuitySet Price TargetHold$14.00 ➝ $12.00High
i
Rating by Dewey Steadman at Canaccord Genuity
5/25/2017MizuhoReiterated RatingBuy ➝ Buy$18.00 ➝ $19.00Low
i
5/22/2017Canaccord GenuitySet Price TargetHold$14.00High
i
Rating by Dewey Steadman at Canaccord Genuity
5/17/2017BMO Capital MarketsReiterated RatingHold$16.00High
i
5/11/2017Canaccord GenuitySet Price TargetHold$14.00Medium
i
Rating by Dewey Steadman at Canaccord Genuity
5/1/2017Canaccord GenuitySet Price TargetHold$14.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
5/1/2017BMO Capital MarketsReiterated RatingHold$15.00Low
i
4/17/2017Canaccord GenuityReiterated RatingHold$14.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
4/13/2017MizuhoReiterated RatingBuy$17.00 ➝ $18.00Low
i
4/11/2017Canaccord GenuityReiterated RatingHold$14.00High
i
Rating by Dewey Steadman at Canaccord Genuity
4/8/2017Royal Bank of CanadaSet Price TargetHold$15.00Medium
i
Rating by Randall Stanicky at Royal Bank of Canada
3/20/2017SVB LeerinkReiterated RatingMarket PerformLow
i
3/15/2017JMP SecuritiesReiterated RatingOutperform$20.00High
i
Rating by Donald Ellis at JMP Securities
3/15/2017Royal Bank of CanadaReiterated RatingSector Perform$15.00High
i
3/14/2017Canaccord GenuitySet Price TargetHold$14.00High
i
Rating by Dewey Steadman at Canaccord Genuity
3/11/2017William BlairReiterated RatingMarket PerformN/A
i
3/3/2017MizuhoBoost Price Target$17.00N/A
i
3/1/2017OppenheimerReiterated RatingHoldN/A
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
3/1/2017Canaccord GenuitySet Price TargetHold$14.00N/A
i
2/28/2017MizuhoReiterated RatingBuy$15.00 ➝ $17.00N/A
i
2/28/2017GuggenheimReiterated RatingBuy$35.00N/A
i
Rating by Louise Chen at Guggenheim
2/21/2017Canaccord GenuityInitiated CoverageHold ➝ Hold$14.00N/A
i
2/6/2017BarclaysLower Price TargetEqual Weight$22.00 ➝ $15.00N/A
i
1/31/2017Susquehanna BancsharesUpgradeNeutral ➝ PositiveN/A
i
1/31/2017MizuhoLower Price TargetBuy$25.00 ➝ $15.00N/A
i
1/30/2017Royal Bank of CanadaReiterated RatingSector Perform$18.00 ➝ $15.00N/A
i
1/27/2017Piper Jaffray CompaniesSet Price TargetHold$12.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
1/20/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$20.00N/A
i
Rating by chris schott at JPMorgan Chase & Co.
1/5/2017CitigroupDowngradeBuy ➝ Neutral$25.00 ➝ $20.00N/A
i
12/11/2016JMP SecuritiesReiterated RatingOutperform$34.00N/A
i
12/7/2016OppenheimerReiterated RatingMarket PerformN/A
i
Rating by Marcus Y. Ho at Oppenheimer Holdings Inc.
11/18/2016JMP SecuritiesReiterated RatingBuyN/A
i
11/11/2016BMO Capital MarketsReiterated RatingHoldN/A
i
11/11/2016MizuhoLower Price TargetBuy$29.00 ➝ $25.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
11/11/2016JMP SecuritiesReiterated RatingOutperform$44.00 ➝ $34.00N/A
i
11/10/2016Susquehanna BancsharesUpgradeNeutral ➝ Positive$20.00N/A
i
11/9/2016Royal Bank of CanadaReiterated RatingOutperform$26.00 ➝ $21.00N/A
i
11/9/2016Royal Bank of CanadaLower Price TargetOutperform$26.00 ➝ $21.00N/A
i
11/8/2016OppenheimerReiterated RatingHoldN/A
i
Rating by Marcus Y. Ho at Oppenheimer Holdings Inc.
10/15/2016GuggenheimReiterated RatingBuy$35.00N/A
i
9/29/2016Northland SecuritiesUpgradeMarket Perform ➝ Outperform$27.00N/A
i
9/29/2016MizuhoReiterated RatingOutperform ➝ Sell$29.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
9/27/2016OppenheimerReiterated RatingMarket PerformN/A
i
Rating by Rohit Vanjani at Oppenheimer Holdings Inc.
9/27/2016Piper Jaffray CompaniesReiterated RatingNeutral$19.00N/A
i
Rating by david amsellem at Piper Jaffray Companies
9/23/2016SVB LeerinkReiterated RatingMarket Perform$22.00N/A
i
Rating by jason gerberry at SVB Leerink LLC
9/19/2016MizuhoReiterated RatingBuy$29.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
9/16/2016CitigroupLower Price TargetBuy$40.00 ➝ $25.00N/A
i
9/8/2016Morgan StanleySet Price TargetHold$15.00 ➝ $16.00N/A
i
Rating by david risinger at Morgan Stanley
8/12/2016MizuhoUpgradeNeutral ➝ Buy$16.00 ➝ $29.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
8/9/2016JPMorgan Chase & Co.Set Price TargetBuy$40.00N/A
i
Rating by chris schott at JPMorgan Chase & Co.
8/9/2016Piper Jaffray CompaniesSet Price TargetHold$18.00 ➝ $19.00N/A
i
Rating by david amsellem at Piper Jaffray Companies
8/9/2016SVB LeerinkReiterated RatingHold$23.00 ➝ $22.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
8/9/2016BMO Capital MarketsReiterated RatingHold$22.00N/A
i
8/9/2016UBS GroupReiterated RatingBuy$30.00N/A
i
8/5/2016Morgan StanleySet Price TargetHold$15.00N/A
i
Rating by David Risinger at Morgan Stanley
7/26/2016JPMorgan Chase & Co.Reiterated RatingOverweight$40.00N/A
i
Rating by Chris Schott at JPMorgan Chase & Co.
7/8/2016Piper Jaffray CompaniesReiterated RatingNeutral$25.00 ➝ $18.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
6/30/2016Morgan StanleyReiterated RatingHoldN/A
i
Rating by David Risinger at Morgan Stanley
6/29/2016OppenheimerReiterated RatingHoldN/A
i
Rating by Rohit Vanjani at Oppenheimer Holdings Inc.
6/29/2016Deutsche Bank AktiengesellschaftReiterated RatingBuy$30.00N/A
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
6/29/2016SVB LeerinkReiterated RatingMarket Perform$23.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
6/29/2016JMP SecuritiesReiterated RatingBuyN/A
i
Rating by Donald Ellis at JMP Securities
6/28/2016BMO Capital MarketsInitiated CoverageMarket Perform$21.00N/A
i
6/25/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/A
i
Rating by Chris Schott at JPMorgan Chase & Co.
6/15/2016Deutsche Bank AktiengesellschaftReiterated RatingBuy$31.00N/A
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
6/13/2016MizuhoUpgradeUnderperform ➝ Neutral$13.00 ➝ $16.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
6/6/2016The Goldman Sachs GroupInitiated CoverageNeutral$20.00N/A
i
5/18/2016Royal Bank of CanadaReiterated RatingSector Perform$26.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
5/18/2016Stifel NicolausLower Price TargetBuy$75.00 ➝ $25.00N/A
i
(Data available from 5/16/2016 forward)
Endo International logo
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $5.61
$5.48
$5.62

50 Day Range

MA: $6.29
$5.16
$7.90

52 Week Range

Now: $5.61
$2.71
$10.89

Volume

2,807,230 shs

Average Volume

3,819,250 shs

Market Capitalization

$1.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.41

Frequently Asked Questions

What sell-side analysts currently cover shares of Endo International?

The following Wall Street research analysts have issued reports on Endo International in the last twelve months: Barclays PLC, Citigroup Inc., Morgan Stanley, Piper Sandler, Royal Bank of Canada, SunTrust Banks, Inc., SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, and Zacks Investment Research.
View the latest analyst ratings for ENDP.

What is the current price target for Endo International?

6 Wall Street analysts have set twelve-month price targets for Endo International in the last year. Their average twelve-month price target is $7.67, suggesting a possible upside of 36.7%. Piper Sandler has the highest price target set, predicting ENDP will reach $12.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $3.00 for Endo International in the next year.
View the latest price targets for ENDP.

What is the current consensus analyst rating for Endo International?

Endo International currently has 2 sell ratings, 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ENDP, but not buy more shares or sell existing shares.
View the latest ratings for ENDP.

What other companies compete with Endo International?

How do I contact Endo International's investor relations team?

Endo International's physical mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company's listed phone number is 011-353-1268-2000 and its investor relations email address is [email protected] The official website for Endo International is www.endo.com.